A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 05 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2018 Planned number of patients changed from 765 to 850.
- 21 Sep 2018 Planned End Date changed from 23 Jul 2020 to 31 Aug 2020.